Which drugs are FDA approved for bispecific therapy and how do they work?

Which drugs are FDA approved for bispecific therapy and how do they work?

There are two bispecific that have been approved by FDA for treating patient with diffuse large B-cell lymphoma.

The indication is a third line setting, meaning that for both patients had received classical chemo immunotherapy and a second line of treatment, which could be, again, chemo immunotherapy. Another form of immunotherapy, or targeted agents or Car-T cells. So patients who have failed two lines of therapy.

One of those is called glofitamab and the other one is called epcoritamab. The similarities is that both engage CD 20 and CD three. So it's the same process.

That is the active process for this bispecific.

There are, however, several differences. One of the difference is that glofitamab is an IV drug, which is an infusion administered as an infusion.

where as epcoritamab is, a subcutaneous drug and administered as a shot. The second difference in when they were developed, the schedule of administration is different with for both drug weekly administration during the first month. But then after the administration, spread with longer interval with glofitamab as compared to epcoritamab.

And the third difference is that glofitamab was developed as, treatment that is finite in time and is administered for 12 cycles, eight months. While epcoritamab was developed with indefinite treatment, as long as the patient benefits from the treatment responds to treatment, or does not have to interrupt for side effects. So drugs that are very similar in the mode of action actually very similar in their efficacy, but difference in the constraints for patient, their side effects,

The schedule of administration one time limited treatment one treatment with indefinite until progression.